Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Breast Cancer Breast Cancer—Metastatic

Breast Cancer—Metastatic

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
 
Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, et al.
Clinical trial information: NCT01942135.
 
Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
 
Dennis J. Slamon, Patrick Neven, Stephen K. L. Chia, et al.
 Clinical trial information: NCT02422615.
 
Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
 
Binghe Xu, Qingyuan Zhang, Pin Zhang, et al.

 Clinical trial information: NCT03927456.

Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.
 
Zhongyu Yuan, Jia-Jia Huang, Xin Hua, et al.

Clinical trial information: NCT01950182.

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).
 
Geoffrey J Lindeman, Rebecca Bowen, Katarzyna Joanna Jerzak, et al.

 Clinical trial information: NCT03584009.

Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).
 
Anne L Loeser, Jeffrey M. Peppercorn, Mark E. Burkard, et al.

 

The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.
 
Leisha A. Emens, Leonard D Goldstein, Peter Schmid, et al.

Clinical trial information: NCT02425891.

Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.
 
Li Chen, Shao Zhimin, Zhonghua Wang, et al.

Clinical trial information: NCT04129996.

Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).
 
Amit Bahl, Jeremy Braybrooke, Alicia Bravo, et al.

Clinical trial information: NCT03048942.